Synthesis and biological evaluation of 3-aryl-quinoxaline-2- carbonitrile 1,4-Di-N-oxide derivatives as hypoxic selective anti-tumor agents

Molecules

Volumn 17, Issue 8, 2012, Pages 9683-9696

  Hu, Yunzhen ^a   Xia, Qing ^a   Shangguan, Shihao ^a   Liu, Xiaowen ^b   Hu, Yongzhou ^a   Sheng, Rong ^a  

^a ZHEJIANG UNIVERSITY   (China)

^b ZHEJIANG UNIVERSITY   (China)

Author keywords

3 aryl 2 quinoxaline carbonitrile 1,4 dioxide; Hypoxic cytotoxic activity; SAR

Indexed keywords

ANTINEOPLASTIC AGENT; NITRILE; QUINOXALINE 2 CARBONITRILE 1,4 DI N OXIDE; QUINOXALINE DERIVATIVE; QUINOXALINE-2-CARBONITRILE 1,4-DI-N-OXIDE;

APOPTOSIS; ARTICLE; CELL HYPOXIA; CHEMISTRY; DRUG EFFECT; DRUG SCREENING; HUMAN; METABOLISM; NEOPLASM; SYNTHESIS; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL HYPOXIA; CELL LINE, TUMOR; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; NEOPLASMS; NITRILES; QUINOXALINES;

EID: 84865527506     PISSN: None     EISSN: 14203049     Source Type: Journal    
DOI: 10.3390/molecules17089683     Document Type: Article

References (25)

1. Martin, B.; Wilson, W.R. Exploiting tumour hypoxia in cancer treatment. Nat. Rev. Cancer 2004, 4, 437-447.
2. Wardman, P. The importance of radiation chemistry to radiation and free radical biology (The 2008 silvanus thompson memorial lecture). Br. J. Radiol. 2009, 82, 89-104.
3. Wilson, W.R.; Hay, M.P. Targeting hypoxia in cancer therapy. Nat. Rev. Cancer 2011, 11, 393-410.
4. Rischin, D.; Peters, L.; Fisher, R.; Macann, A.; Denham, J.; Poulsen, M.; Jackson, M.; Kenny, L.; Penniment, M.; Corry, J.; et al. Tirapazamine, cisplatin, and radiation versus fluorouracil, cisplatin, and radiation in patients with locally advanced head and neck cancer: A randomized phase II trial of the trans-tasman radiation oncology group (TROG 98.02). J. Clin. Oncol. 2005, 23, 79-87.
5. Rischin, D.; Peters, L.; ÓSullivan, B.O.; Giralt, J.; Fisher, R.; Yuen, K.; Trotti, A.; Bernier, J.; Bourhis, J.; Ringash, J.; et al. Tirapazamine, cisplatin, and radiation versus cisplatin and radiation for advanced squamous cell carcinoma of the head and neck (TROG 02.02, HeadSTART): A phase III trial of the trans-tasman radiation oncology group. J. Clin. Oncol. 2010, 28, 2989-2996.
6. Monge, A.; Martinez-Crespo, F.J.; Lopez, A.; Palop, J.A.; Narro, S.; Senador, V.; Marin, A.; Sainz, Y.; Gonzalez, M. Hypoxia-selective agents derived from 2-Quinoxalinecarbonitrile 1,4-Di-Noxides. J. Med. Chem. 1995, 38, 4488-4494.
7. Hay, M.P.; Hicks, K.O.; Pchalek, P.; Lee, H.H.; Blaser, A.; Pruijn, F.B.; Anderson, R.F.; Shinde, S.S.; Wilson, W.R.; Denny, W.A. Tricyclic [1,2,4]triazine 1,4-dioxides as hypoxia selective cytotoxins. J. Med. Chem. 2008, 51, 6853-6865.
8. Solano, B.; Junnotula, V.; Marín, A.; Villar, R.; Burguete A.; Vicente E.; Pérez-Silanes, S.; Aldana, I.; Monge, A.; Dutta, S.; et al. Synthesis and biological evaluation of new 2-arylcarbonyl- 3- trifluoromethylquinoxaline 1,4-di-N-oxide derivatives and their reduced analogues. J. Med. Chem. 2007, 50, 5485-5492.
9. Magda, M.F.I.; Kamelia, M.A.; Eman, N.; Dalia, H.S.; Yousry, A.A. New quinoxaline 1, 4-di-Noxides: Anticancer and hypoxia-selective therapeutic agents. Eur. J. Med. Chem. 2010, 45, 2733-2738.
10. Hicks, K.O.; Siim, B.G.; Jaiswal, J.K.; Pruijn, F.B.; Fraser, A.M.; Patel, R.; Hogg, A.; Liyanage, S.; Dorie, M.J.; Brown, M.; et al. Pharmacokinetic/Pharmacodynamic modeling identifies SN30000 and SN29751 as tirapazamine analogues with improved tissue penetration and hypoxic cell killing in tumors. Clin. Cancer Res. 2010, 16, 4946-4957.
11. Jiang, F.Q.; Yang, B.; Fan, L.L.; He, Q.J.; Hu, Y.Z. Synthesis and hypoxic-cytotoxic activity of some 3-amino-1,2,4-benzotriazine-1,4-dioxide derivatives. Bioorg. Med. Chem. Lett. 2006, 16, 4209-4213.
12. Xia, Q.; Zhang, L.; Zhang, J.; Sheng, R.; Yang, B.; He, Q.J.; Hu, Y.Z. Synthesis, hypoxiaselective cytotoxicity of new 3-amino-1,2,4-benzotriazine-1,4- dioxide derivatives Euro. J. Med. Chem. 2011, 46, 919-926.
13. Jiang, F.Q.; Weng, Q.J.; Sheng, R.; Xia, Q.; He, Q.J.; Yang, B.; Hu, Y.Z. Synthesis, structure and hypoxic cytotoxicity of 3-amino-1,2,4-benzotriazine-1, 4-dioxide derivatives Arch. Der. Pharm. 2007, 340, 258-263.
14. Sheng, R.; Xu, Y.; Weng, Q. J.; Xia, Q.; He, Q.J.; Yang, B.; Hu, Y.Z. Synthesis and cytotoxic activity of 3-phenyl-2-thio-quinoxaline1,4-dioxide derivatives in hypoxia and in normoxia. Drug. Discov. Ther. 2007, 1, 119-123.
15. Weng, Q.J.; Wang, D.D.; Guo, P.; Fang, L.; Hu, Y.Z. He, Q.J.; Yang, B. Q39, a novel synthetic quinoxaline 1,4-di-N-oxide compound with anti-cancer activity in hypoxia. Eur. J. Pharmacol. 2008, 581, 262-269.
16. Weng, Q.J.; Zhang, J.; Cao, J.; Xia, Q.; Wang, D.D.; Hu, Y.Z.; Sheng, R.; Wu, H.H.; Zhu, D.F.; Zhu, H.; et al. Q39, a quinoxaline 1,4-di-N-oxide derivative, inhibits hypoxia-inducible factor-1α expression and the Akt/mTOR/4E-BP1 signaling pathway in human hepatoma cells. Invest New Drug. 2011, 29, 1177-1187.
17. Zarranz, B.; Jaso, A.; Aldana, I.; Monge, A.; Maurel, S.; Deharo, E.; Jullian, V.; Sauvain, M. Synthesis and antimalarial activity of new 3-arylquinoxaline-2-carbonitrile derivatives. Arzneim. Forsch. 2005, 55, 754-761.
18. Vicente, E.; Duchowicz, P.R.; Benitez, D.; Castro, E.A.; Cerecetto, H.; Gonzalez, M.; Monge, A. Anti-T. cruzi activities and QSAR studies of 3-arylquinoxaline-2-carbonitrile di-N-oxides. Bioorg. Med. Chem. Lett. 2010, 20, 4831-4835.
19. Vicente, E.; Lima, L.M.; Bongard, E.; Charnaud, S.; Villar, R.; Solano, B.; Burguete, A.; Perez-Silanes, S.; Aldana, I.; Vivas, L.; Monge, A. Synthesis and structure-activity relationship of 3-phenylquinoxaline 1,4-di-N-oxide derivatives as antimalarial agents. Eur. J. Med. Chem. 2008, 43, 1903-1910.
20. Puterová, Z.; Andicsová, A.; Végh, D. Synthesis of π-conjugated thiophenes starting from substituted 3-oxopropanenitriles via gewald reaction. Tetrahedron 2008, 64, 11262-11269.
21. Dornow, A.; Kuhlcke, I.; Baxmann, F. Über einige derivate der benzoylessigsäure. Chem. Ber. 1949, 82, 254-257.
22. Alon, H.; Lena, L.; Michal, W.; Iris, O.G.; Abraham, N.; Amnon, H. De Novo parallel design, synthesis and evaluation of inhibitors against the reverse transcriptase of human immunodeficiency virus type-1 and drug-resistant variants. J. Med. Chem. 2007, 50, 2370-2383.
23. Ridge, D.N.; Hanifin, J.W.; Harten, L.A.; Johnson, B.D.; Menschik, J.; Nicolau, G.; Sloboda, A.E.; Watts, D.E. Potential antiarthritic agents. 2. Benzoylacetonitriles and. beta.-aminocinnamonitriles. J. Med. Chem. 1979, 22, 1385-1389.
24. Gaughran, R.J.; Picard, J.P.; Kaufman, J.V.R. Contribution to the chemistry of benzfuroxan and benzfurazan derivatives. J. Am. Chem. Soc. 1954, 76, 2233-2236.
25. Yang, B.; Patrick, R.C. Tirapazamine cytotoxicity for neuroblastoma is p53 Dependent. Clin. Cancer. Res. 2005, 11, 2774-2780.